Release Date: December 10, 2022
Expiration Date: March 2, 2023
Activity Overview
This educational activity is an archive of the live virtual presentation held on December 9, 2022.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This activity is directed toward medical oncologists, hematologic oncologists, hematologists, pathologists, nurses, and other healthcare professionals involved in the treatment of BPDCN.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Explain the clinical presentation, cytogenetics, and pathophysiological mechanisms of BPDCN
- Apply criteria for the timely diagnosis of BPDCN, including methods for differential diagnosis, through optimization of multidisciplinary collaboration
- Assess the clinical profiles of current and emerging CD123-targeted therapeutic approaches that have been investigated for the treatment of patients with BPDCN
- Incorporate updated guidelines and pivotal trial data on current/emerging agents targeting CD123 into personalized treatment plans for patients with BPDCN
Naveen Pemmaraju, MD
Associate Professor
Department of Leukemia
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Consultant: Protagonist Therapeutics, Cimeio Therapeutics, Immunogen, AbbVie, Astellas Pharma US, Inc., CTI BioPharma, PharmaEssentia, Patient Power, Stemline Therapeutics, Inc., Novartis, Incyte, Bristol Myers Squibb, ClearView Healthcare Partners, Aptitude Health, Blueprint Medicines; Other: Scientific Advisory Board or Preceptorship: Incyte, Menarini Group, Pacylex, Blueprint Medicines, CTI BioPharma, Cancer.Net, CareDx, EUSA Pharma, Inc., Novartis, PharmaEssentia, Protagonist Therapeutics, Dava Oncology, AbbVie, Curio Science LLC, Aplastic Anemia & MDS International Foundation Postgraduate Institute for Medicine, Neopharm, Stemline Therapeutics, Inc.
Monica L. Guzman, PhD
Associate Professor of Pharmacology in Medicine
Weill Cornell Medical College
New York, NY
Disclosures: Grant/Research Support: BridgeMedicines; Consultant: BridgeMedicines, Janssen; Speakers’ Bureau: SeqRx
Andrew A. Lane, MD, PhD
Associate Professor, Medicine
Harvard Medical School
Associate Professor, Medical Oncology
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Grant/Research Support: Stemline Therapeutics, AbbVie; Consultant: Qiagen, Adaptimmune, Cimeio
Muzaffar H. Qazilbash, MD
Professor of Medicine
Director, Myeloma Transplantation and Cellular Therapy
Department of Stem Cell Transplantation and Cellular Therapy
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research Support: Janssen, Angiocrine, NexImmune, Bioline
Disclosures/Disclaimers
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies, with the following exception (Sara Fagerlie, PhD, freelance medical director: Former Consultant: Adaptive Biotechnologies).
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
